Publication
Testing ERBB2 p.L755S kinase domain mutation as a druggable target in a patient with advanced colorectal cancer.
Authors not recorded
Cold Spring Harb Mol Case Stud2016PMID 27626067PMC5002925stubpubmedProvenance
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
No abstract stored. Read on PubMed
Linked entities
Linked entities (6)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 6
- cancerColorectal Adenocarcinomacivic_curation1.00
- drugFluorouracilcivic_curation1.00
- drugLeucovorincivic_curation1.00
- drugTrastuzumabcivic_curation1.00
- geneERBB2civic_curation1.00
- variantERBB2 L755Scivic_curation1.00
Curated evidence
Evidence citing this paper (1)
civicProvenance
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 27626067
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| ERBB2 L755S1 | ||||||||
| Fluorouracil + Leucovorin + TrastuzumabCombination | Colorectal Adenocarcinoma | Predictive | C | Does Not Support Sensitivity Response | 3 | accepted | EID4955Patient was a 35 year old male who was treated with pseudoadjuvant FOLFOX chemotherapy. Patient relapsed and was found to have an ERBB2 L755S kinase domain mutation along with mutations in APC and BRA… (full text at CIViC) PMID 27626067 · Aung et al., 2016 · Open in CIViC | civic |